<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Allogeneic bone marrow transplantation (BMT) is potentially curative therapy for <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and marrow failure </plain></SENT>
<SENT sid="1" pm="."><plain>Ninety-two patients have received allogeneic BMT at Oklahoma Memorial Hospital in the past 10 years </plain></SENT>
<SENT sid="2" pm="."><plain>Patients with <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; N = 30), <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>; N = 27), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL; N = 12), <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; N = 8), <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (N = 8), and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (N = 7) were treated with a variety of myeloablative preparative regimens </plain></SENT>
<SENT sid="3" pm="."><plain>The major causes of mortality were <z:mp ids='MP_0001794'>bacterial</z:mp>, <z:mp ids='MP_0001799'>viral</z:mp>, and <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e>, or disease relapse </plain></SENT>
<SENT sid="4" pm="."><plain>Standard and high risk (refractory or multiply-<z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">relapsed disease</z:e>) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:mp ids='MP_0005481'>CML</z:mp>, and ALL patients had median survivals of 14.5 months vs. 3 months, &gt; 18 months vs. 9 months, and 10 months vs. 4.5 months (p = 0.01), respectively </plain></SENT>
<SENT sid="5" pm="."><plain>At 7.5 years median follow-up, 71% of the <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> patients are disease-free </plain></SENT>
<SENT sid="6" pm="."><plain>Guidelines for the optimal time for BMT have been developed that encourage transplantation earlier in the course of the disease, thus facilitating better outcomes with these otherwise fatal disorders </plain></SENT>
</text></document>